Allergy Therapeutics plc (LON:AGY – Get Free Report) hit a new 52-week low on Thursday . The company traded as low as GBX 5 and last traded at GBX 5.44, with a volume of 679616 shares trading hands. The stock had previously closed at GBX 5.90.
Allergy Therapeutics Price Performance
The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58. The firm has a market capitalization of £344.49 million, a price-to-earnings ratio of -5.61, a P/E/G ratio of -30.70 and a beta of 0.87. The company has a fifty day moving average price of GBX 7.42 and a two-hundred day moving average price of GBX 9.64.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Recommended Stories
- Five stocks we like better than Allergy Therapeutics
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
- Tesla: After a Rough Quarter, 2 Very Different Futures Come Into Focus
- Why NXP Semiconductors Could Be the AI Stock Everyone Is Missing
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
